

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

NCT06414954

Status	RECRUITING
Phase	Phase 2
Sponsor	NMD Pharma A/S
Enrollment	84 participants

Key Eligibility Criteria

Inclusion (7)

- Participant must be a male or female being 18 or more, at the time of signing the informed consent
- Diagnosis of MG, MGFA class II, III or IV
- Documented positive AChR or MuSK antibody test.
- Participant must be able to swallow tablets
- Body mass index between 18 and 35 kg/m², inclusive, at screening, and with a minimum weight of 40 kg
- ... and 2 more (see full listing online)

Exclusion (5)

- Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study
- Participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study
- Participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to Day 1
- Participants with history of poor compliance with relevant MG therapy
- Female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding

Locations (39 total)

Profound Research LLC, Carlsbad, California, United States
University of California Irvine Medical Center, Irvine, California, United States
University of Colorado Neuromuscular Division, Aurora, Colorado, United States
... and 36 more locations

<https://clinicaltrials.gov/study/NCT06414954>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).